Please login to the form below

Not currently logged in
Email:
Password:

Random42 wins Queen’s Award for Enterprise

Will celebrate during the royal reception this summer

Random42

Random42 Scientific Communication has been recognised for its excellence in international trade, picking up a Queen’s Award for Enterprise last month.

The awards have a long history celebrating ‘exceptional’ UK businesses and are considered the most ‘prestigious’ business awards in the UK.

The category of International Trade is said to recognise businesses that have demonstrated substantial international growth in overseas earnings and commercial success within their sector.

Ben Ramsbottom, CEO and medical director of Random42, said: “It is this success in the US that has won us The Queen’s Award.

“We operate in a growing market and have taken advantage of that to substantially expand the level of business we do in the US.”

The London, UK-based group aims to become a world-leader in science education, both from a pharma perspective and the “broader research community”.

Random42, who specialises in medical animation and education, scientific virtual reality, interactive and visually engaging solutions from pharma and biotech companies, will celebrate their award during a royal reception this summer.

Article by
Gemma Jones

4th May 2018

From: Marketing

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics